Literature DB >> 6799548

Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

G B Pier.   

Abstract

The safety and immunogenicity of a high molecular weight polysaccharide from immunotype 1 Pseudomonas aeruginosa were tested in a dose response fashion in adult volunteers. The vaccine lacked toxicity and pyrogenicity for experimental animals. Doses of 50, 75, 150, or 250 microgram were given to groups of individuals as a single dose subcutaneous injection. Doses of 150 and 250 microgram were associated with a significant rise in binding and opsonic antibody at 2 wk postimmunization. Titers remained unchanged for up to 6 mo. The vaccine was almost devoid of toxicity, eliciting no more than a slightly sore and tender arm at the site of injection. High molecular weight polysaccharide antigen appears to induce a good immune response following vaccination that is effective in mediating opsonophagocytic killing of live P. aeruginosa organisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6799548      PMCID: PMC370979          DOI: 10.1172/jci110453

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Advances in the management of Pseudomonas aeruginosa infections in cancer patients.

Authors:  G P Bodey; V Rodriguez
Journal:  Eur J Cancer       Date:  1973-06       Impact factor: 9.162

2.  Immunization against Pseudomonas in infection after thermal injury.

Authors:  J Wesley; A Fisher; M W Fisher
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

3.  Type-specific immunity in pseudomonas diseases.

Authors:  J G Crowder; M W Fisher; A White
Journal:  J Lab Clin Med       Date:  1972-01

4.  Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

5.  Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

Authors:  G B Pier; H F Sidberry; J C Sadoff
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

6.  Pseudomonas bacteremia. Review of 108 cases.

Authors:  M R Flick; L E Cluff
Journal:  Am J Med       Date:  1976-04       Impact factor: 4.965

7.  A new polyvalent Pseudomonas vaccine.

Authors:  J M Miler; J F Spilsbury; R J Jones; E A Roe; E J Lowbury
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

8.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

9.  Correlation of the biologic responses of C3H/HEJ mice to endotoxin with the chemical and structural properties of the lipopolysaccharides from Pseudomonas aeruginosa and Escherichia coli.

Authors:  G B Pier; R B Markham; D Eardley
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

10.  Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.

Authors:  R J Jones; E A Roe; J L Gupta
Journal:  Lancet       Date:  1980-12-13       Impact factor: 79.321

View more
  36 in total

1.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum.

Authors:  T R Anderson; T C Montie
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

3.  Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene.

Authors:  M Duchêne; A Schweizer; F Lottspeich; G Krauss; M Marget; K Vogel; B U von Specht; H Domdey
Journal:  J Bacteriol       Date:  1988-01       Impact factor: 3.490

4.  T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice.

Authors:  W G Powderly; G B Pier; R B Markham
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

5.  Effect of oral immunization with Pseudomonas aeruginosa on the development of specific antibacterial immunity in the lungs.

Authors:  J Freihorst; J M Merrick; P L Ogra
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

6.  Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.

Authors:  G B Pier; S E Bennett
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

7.  Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice.

Authors:  G C Tsay; M S Collins
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

8.  Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice.

Authors:  M Pollack; G B Pier; R K Prescott
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

9.  Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.

Authors:  G B Pier; M Pollack; M Cohen
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

10.  Further purification and characterization of high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

Authors:  G B Pier; M Cohen; H Jennings
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.